Merck's Backbone Is Cardiovascular, Infectious Disease After Pipeline Integration
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's late-stage pipeline includes more than 40 compounds in Phase II and Phase III development after combining with Schering-Plough's assets.